Introduction: The Status of CRXT Stock Today

If you are looking to invest in crxt stock (Clarus Therapeutics Holdings, Inc.) today, you will quickly find that the ticker is completely inactive, unavailable, or listed as defunct on major trading platforms. The stock, which previously traded on the NASDAQ under the symbol CRXT and later on the over-the-counter (OTC) market under the ticker CRXTQ, has officially ceased to exist.

On September 5, 2022, faced with a severe liquidity crisis, a heavy debt burden, and the inability to raise fresh capital, Clarus Therapeutics filed for Chapter 11 bankruptcy protection. Following a court-supervised auction, the company's primary asset, JATENZO, was sold to a competitor. On February 28, 2023, Clarus's liquidation plan became effective, resulting in the absolute cancellation, extinguishment, and destruction of all outstanding shares of common stock. Retail investors who held the stock through the bankruptcy process had their shares wiped out to zero, with no distributions or recoveries.

For anyone researching the history of crxt stock, this post-mortem provides a highly detailed, comprehensive analysis of what went wrong. From its highly publicized SPAC merger to its crushing patent battles, dilutive equity offerings, and the ongoing multi-million dollar legal warfare in 2026, this is the definitive guide to the rise and fall of Clarus Therapeutics.

The Rise: JATENZO and the Promise of Oral Testosterone

To understand the immense excitement that once surrounded crxt stock, one must understand the clinical breakthrough of its primary product, JATENZO (testosterone undecanoate).

Clarus Therapeutics was founded with a clinical goal: to revolutionize the treatment of male hypogonadism (testosterone deficiency). Hypogonadism is a widespread medical condition that affects millions of men globally, leading to chronic fatigue, loss of muscle mass, decreased bone density, low libido, and mood disorders. For decades, testosterone replacement therapy (TRT) options were limited and highly inconvenient. Patients had to rely on:

• Intramuscular Injections: Highly effective but painful, requiring frequent doctor visits or self-injection, and causing extreme "peaks and valleys" in hormone levels.
• Topical Gels and Solutions: Easy to apply, but they carried a black-box warning due to the severe risk of accidental transfer to women and children through physical contact.
• Transdermal Patches: Prone to causing skin irritation and often failing to adhere properly.

Historically, oral testosterone was viewed as the "holy grail" of TRT, but early formulations (such as methyltestosterone) were notorious for causing severe liver toxicity (hepatotoxicity) and liver tumors.

Clarus solved this safety hurdle with JATENZO, a softgel capsule utilizing testosterone undecanoate. Rather than being absorbed via the portal vein and passing directly through the liver (first-pass metabolism), JATENZO is absorbed through the lymphatic system via chylomicrons. This completely bypassed the liver, dramatically reducing the risk of hepatotoxicity.

In March 2019, the FDA officially approved JATENZO, making it the first oral testosterone undecanoate formulation approved in the United States in over 60 years. When Clarus commercialized the drug in early 2020, Wall Street took notice. The addressable market was massive, and JATENZO held a clear competitive advantage in patient convenience. However, the commercial launch coincided with the onset of the COVID-19 pandemic, which restricted sales representatives from visiting clinics, severely hampering early adoption and setting the stage for a critical cash shortage.

The SPAC Trap: How BHAC Became CRXT and Starved the Company of Cash

Desperate for capital to fund a nationwide commercial expansion of JATENZO, Clarus Therapeutics opted to go public. Rather than pursuing a traditional Initial Public Offering (IPO), Clarus chose to merge with a Special Purpose Acquisition Company (SPAC) called Blue Water Acquisition Corp., which traded under the ticker BHAC.

On September 9, 2021, the business combination was finalized, and the newly merged entity began trading on the NASDAQ under the ticker CRXT.

At the time, the SPAC market was experiencing an unprecedented boom. Investors were drawn to "blank check" companies as rapid vehicles to bring exciting startups to public markets. Under the SPAC structure, Blue Water Acquisition Corp. held roughly $57.5 million in a "cash-in-trust" account, which was supposed to be delivered to Clarus upon completion of the merger to fund its operations.

However, SPAC mergers possess a structural flaw that proved fatal for Clarus: redemption rights. Prior to a SPAC merger closing, public shareholders have the right to redeem their shares and claw back their $10-per-share cash contribution from the trust if they do not wish to participate in the combined company.

By late 2021, the market's enthusiasm for pre-revenue and highly leveraged biotech SPACs was collapsing. Consequently, when the merger vote took place, an overwhelming majority of BHAC shareholders elected to redeem their shares. This "redemption wave" starved Clarus of the cash it desperately needed. Instead of receiving tens of millions of dollars from the SPAC trust, the vast majority of the cash was clawed back by redeeming investors, leaving Clarus with a fraction of the expected capital.

To proceed, Clarus had to rely on a Private Investment in Public Equity (PIPE) and expensive debt structures. This initial capital shortfall crippled the company from day one, forcing them to commercialize a major new drug with an empty treasury.

The War of Attrition: Clarus vs. Lipocine Patent Litigation

Compounding its financial misery, Clarus was locked in a bitter, multi-year patent battle with Lipocine Inc. (NASDAQ: LPCN). Lipocine was developing its own competing oral testosterone undecanoate product, Tlando.

The legal warfare took place on multiple fronts, including the U.S. District Court for the District of Delaware and the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). Lipocine accused Clarus of infringing upon its intellectual property, while Clarus aggressively fought to have Lipocine's patents declared invalid.

The litigation was a classic corporate war of attrition:

• May 2021: Clarus scored a major legal victory when the Delaware District Court granted its motion for summary judgment, declaring Lipocine's patent claims invalid.
• July 2021: The two companies reached a comprehensive settlement, agreeing to dismiss all pending patent infringement lawsuits and patent interference proceedings.

Under the terms of the confidential settlement, Clarus did not have to pay a direct cash settlement to Lipocine. However, the damage to Clarus's balance sheet had already been done. The legal fees associated with defending JATENZO's market exclusivity over several years had drained millions of dollars in cash—resources that should have been deployed toward sales, marketing, and commercial scaling. Furthermore, Lipocine's Tlando eventually received FDA approval, introducing direct competition to a market Clarus had struggled to capture.

The Financial Death Spiral: Dilution, Debt, and the Chapter 11 Filing

By early 2022, the financial reality of Clarus Therapeutics was grim. The company was trapped in a classic "death spiral" characterized by high operating expenses, slow revenue growth, heavy debt, and extreme dilution.

A look at Clarus's Q2 2022 financial statements reveals the mathematical impossibility of their survival:

• Net Revenue: Clarus reported JATENZO net sales of approximately $6.1 million.
• Operating Expenses: The cost of sales, marketing, research and development, and general administrative overhead reached a staggering $18.3 million.
• Net Loss: The company was burning through cash at a rate of over $12 million per quarter.

As of June 30, 2022, Clarus had less than $10 million in cash and cash equivalents remaining on its balance sheet. To keep the lights on, management turned to the public markets, but because crxt stock was trading at depressed levels, any equity raise would be highly dilutive.

In April 2022, Clarus announced the pricing of an upsized $30.0 million underwritten public offering of common stock and warrants. The "upsized" nature of the deal meant the company had to issue a massive volume of cheap shares and warrants to attract institutional buyers. The announcement was a disaster for retail investors, causing crxt stock to lose more than 22% of its value in a single trading session.

To make matters worse, Clarus had entered into a senior secured credit facility. The debt agreement contained strict financial covenants, including requirements for minimum cash balances and trailing net revenue targets. As cash depleted and JATENZO sales failed to meet targets, Clarus breached these covenants. This gave the secured lenders the legal right to declare a default and demand immediate repayment of the outstanding debt.

With no cash, no access to capital markets, and a looming default, Clarus's board of directors, led by CEO Dr. Robert Dudley, realized that the company was no longer a viable entity. On September 5, 2022, Clarus Therapeutics Holdings, Inc. officially filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.

The Asset Auction: Tolmar Steps In to Save JATENZO

Upon entering Chapter 11 bankruptcy, Clarus did not seek to restructure its debts and continue operating. Instead, the company initiated a court-supervised sale of its assets under Section 363 of the Bankruptcy Code. The primary objective was to conduct a competitive auction for JATENZO, find a well-capitalized pharmaceutical buyer, and use the proceeds to pay off its senior secured lenders.

Raymond James was retained as the investment bank to run the bidding process, reaching out to dozens of potential buyers in the pharmaceutical industry.

On October 14, 2022, Clarus concluded its competitive bidding process. The winning bidder was Tolmar, Inc., a privately held pharmaceutical firm specializing in urology, oncology, and men's health.

The transaction details included:

• The Acquisition: Tolmar agreed to acquire all rights, patents, trademarks, and inventory associated with JATENZO.
• The Price: Tolmar paid approximately $30 million to acquire the asset.
• The Approval: On October 26, 2022, the bankruptcy court officially approved the sale, and the transaction closed shortly thereafter.

For patients who relied on JATENZO, the sale was a positive outcome. Tolmar possessed an established, highly successful sales force and had the capital necessary to support the drug's long-term commercialization. JATENZO remained on the market, uninterrupted.

However, for the holders of crxt stock, the auction was the final nail in the coffin.

The Plan of Liquidation: Why CRXTQ Stock is Worthless

A common misconception among retail investors is that when a bankrupt company sells its assets, the stock owners will receive a payout. Under U.S. corporate law, this is virtually impossible due to the Absolute Priority Rule.

The Absolute Priority Rule dictates the exact order in which assets must be distributed in a liquidation:

1. Secured Creditors: Lenders holding collateral (e.g., senior debt holders) are paid first.
2. Administrative Claims: Bankruptcy lawyers, advisors, and restructuring consultants are paid next.
3. Unsecured Creditors: Trade vendors, suppliers, and bondholders are paid.
4. Equity Holders (Stockholders): Preferred and common stockholders are at the absolute bottom of the hierarchy.

In the case of Clarus Therapeutics, the $30 million purchase price paid by Tolmar was not even enough to fully satisfy the claims of the senior secured lenders. Consequently, there was absolutely zero cash left over for unsecured creditors, let alone equity holders.

On February 9, 2023, the bankruptcy court entered an order confirming the First Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation of Clarus Therapeutics Holdings, Inc.. The plan went into effect on February 28, 2023.

Under the terms of the confirmed liquidation plan:

• All outstanding shares of common stock, trading under the ticker CRXTQ, were formally and permanently cancelled, extinguished, and declared worthless.
• Shareholders were explicitly barred from receiving any recovery, cash, or stock in any future entity.
• The company's corporate charter was dissolved, and Clarus Therapeutics Holdings, Inc. legally ceased to exist.

Following the plan's implementation, FINRA issued a notification to all broker-dealers confirming the worthless status of the security. Brokerage firms subsequently removed the CRXTQ ticker from their platforms and deleted the shares from investor accounts, forcing shareholders to realize a 100% loss.

Ongoing Drama (2024–2026): The SPAC Misconduct Lawsuits

While the equity was wiped out and the company dissolved, the legal fallout of the Clarus Therapeutics collapse has persisted. Between 2024 and 2026, a major legal battle has played out in the Delaware bankruptcy courts, placing the mechanics of the original SPAC merger under intense judicial scrutiny.

When the Chapter 11 plan was confirmed, a Liquidating Trust was established to recover any remaining assets or legal claims for the benefit of unpaid creditors. Gavin/Solmonese LLC was appointed as the Plan Administrator.

On September 3, 2024, the Plan Administrator filed an explosive adversary complaint (Case No. 24-50125) in the bankruptcy court. The lawsuit targets the former directors of Blue Water Acquisition Corp. (the SPAC), specifically focusing on its former CEO and Chairman of the Board, Y. Joseph Hernandez. The lawsuit also names Maxim Group LLC (the SPAC's financial advisor) and Ellenoff Grossman & Schole LLP (the legal counsel).

The Core of the Lawsuit: The complaint alleges that the SPAC's directors breached their fiduciary duties of loyalty, care, and good faith by forcing through the business combination with Clarus in September 2021.

The Plan Administrator argues that:

1. Insider Self-Interest: Under the SPAC "promote" structure, the sponsors and directors stood to receive millions of dollars in valuable "founder shares" virtually for free, but only if they successfully completed a merger before the SPAC's two-year deadline. If no merger occurred, the SPAC would liquidate, and the sponsors' investment would be wiped out.
2. Ignoring Red Flags: The complaint alleges that the directors knew, or should have known, that Clarus was functionally insolvent, carried a massive debt burden, and was structurally incapable of commercializing JATENZO with the capital remaining after the massive shareholder redemptions.
3. Rushing a Bad Deal: Rather than calling off the merger to protect public shareholders, the insiders pushed the transaction through to secure their personal payouts, resulting in the rapid bankruptcy of the combined company less than a year later.

The lawsuit seeking tens of millions of dollars in damages has continued to progress through 2025 and 2026. While any potential settlement or court judgment will go entirely to the unpaid creditors of the Liquidating Trust, this ongoing litigation has become a landmark case, highlighting the systemic conflicts of interest inherent in the SPAC boom.

Crucial Lessons for Biotech and SPAC Investors

The rise and fall of crxt stock provides critical structural warnings for retail investors navigating the stock market:

1. The "Single-Asset" Biotech Mirage

Many retail investors fall in love with the scientific or clinical profile of a biotech company's drug. They assume that FDA approval guarantees financial success. Clarus Therapeutics proved that securing FDA approval is merely the first step. The subsequent commercialization phase is incredibly capital-intensive and fraught with risk. If a company does not possess a deep treasury or an established partner, the cost of scaling sales can easily bankrupted them before they reach profitability.

2. The Misaligned Incentives of SPACs

SPACs are highly complex financial instruments. The sponsors of a SPAC are highly motivated to close any deal, regardless of quality, because their "promote" shares only become valuable upon the completion of a business combination. Public retail investors bear all the operational risk of the target company, while the sponsors are insulated by their low-cost founder shares. Always examine the balance sheet, debt load, and expected cash-after-redemptions of a SPAC target.

3. Bankrupt "Q" Stocks Are Not Safe Long-Term Investments

When a stock is delisted and moves to the OTC Pink sheets with a "Q" modifier, it often attracts speculative "meme" traders hoping for a short squeeze or a restructuring miracle. In the vast majority of cases, the absolute priority rule ensures that common equity holders are completely wiped out. Buying a stock like CRXTQ during Chapter 11 is not investing; it is highly dangerous speculation with a statistically near-certain outcome of a 100% loss.

Frequently Asked Questions (FAQ)

Can I still trade CRXT or CRXTQ stock?

No. All shares of Clarus Therapeutics Holdings, Inc. (formerly traded under CRXT and CRXTQ) were officially cancelled, extinguished, and declared worthless on February 28, 2023. The tickers have been deleted, and the stock can no longer be bought, sold, or traded on any exchange.

What is the difference between CRXT and CRXTQ?

CRXT was the ticker symbol used when Clarus Therapeutics was actively listed on the NASDAQ exchange. CRXTQ was the ticker symbol assigned when the stock was delisted and moved to the over-the-counter (OTC) market following its Chapter 11 bankruptcy filing. The "Q" modifier is added by financial regulators to warn investors that the company is currently in bankruptcy.

Can I buy JATENZO today?

Yes. JATENZO remains fully approved by the FDA and available for prescription in the United States. Following the bankruptcy auction, the drug was acquired by Tolmar, Inc., which successfully integrated JATENZO into its specialized urology sales pipeline.

Why didn't CRXT stock owners receive a payout when JATENZO was sold?

Under U.S. bankruptcy law, secured and administrative creditors must be paid in full before common stockholders can receive any distribution. Because the $30 million purchase price paid by Tolmar was not even enough to fully satisfy Clarus's senior secured debt, there was no remaining cash for equity holders.

Who is being sued over the Clarus Therapeutics bankruptcy?

The Plan Administrator for the Clarus Liquidation Trust is currently pursuing an active lawsuit against former CEO Y. Joseph Hernandez, the SPAC's board of directors, the underwriter Maxim Group, and the law firm Ellenoff Grossman & Schole. The lawsuit alleges that they breached their fiduciary duties by pushing through a highly conflicted and financially unviable SPAC merger.

Can I use my CRXT stock losses for tax write-offs?

Yes. Since the stock was officially declared worthless and cancelled in 2023, investors who held the shares through the liquidation plan can typically claim a capital loss on their tax returns. You should consult a certified public accountant (CPA) or tax professional to properly file a worthless securities claim (typically using IRS Form 8949).

Conclusion

The post-mortem of crxt stock stands as a sobering warning in the annals of modern biotech and SPAC investing. Clarus Therapeutics possessed a genuinely innovative, FDA-approved medical breakthrough in JATENZO. Yet, the combination of a starved cash treasury due to extreme SPAC redemptions, an exhausting patent war with Lipocine, aggressive dilutive equity offerings, and a heavy senior debt load created a financial storm that the company could not weather.

For retail investors, the story of Clarus is a vivid reminder that clinical success does not always translate to financial success, that SPAC incentives are often heavily stacked against public shareholders, and that holding a stock through Chapter 11 bankruptcy is a direct path to a total loss.